166 related articles for article (PubMed ID: 30856283)
1. AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3.
Tokunaga R; Cao S; Naseem M; Battaglin F; Lo JH; Arai H; Loupakis F; Stintzing S; Puccini A; Berger MD; Soni S; Zhang W; Mancao C; Salhia B; Mumenthaler SM; Weisenberger DJ; Liang G; Cremolini C; Heinemann V; Falcone A; Millstein J; Lenz HJ
Int J Cancer; 2019 Oct; 145(8):2082-2090. PubMed ID: 30856283
[TBL] [Abstract][Full Text] [Related]
2. Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
Tokunaga R; Cao S; Naseem M; Lo JH; Battaglin F; Puccini A; Berger MD; Soni S; Millstein J; Zhang W; Stintzing S; Loupakis F; Cremolini C; Heinemann V; Falcone A; Lenz HJ
Clin Colorectal Cancer; 2019 Mar; 18(1):e8-e19. PubMed ID: 30293873
[TBL] [Abstract][Full Text] [Related]
3. Impact of genetic variations in the MAPK signaling pathway on outcome in metastatic colorectal cancer patients treated with first-line FOLFIRI and bevacizumab: data from FIRE-3 and TRIBE trials.
Berger MD; Stintzing S; Heinemann V; Yang D; Cao S; Sunakawa Y; Ning Y; Matsusaka S; Okazaki S; Miyamoto Y; Suenaga M; Schirripa M; Soni S; Zhang W; Falcone A; Loupakis F; Lenz HJ
Ann Oncol; 2017 Nov; 28(11):2780-2785. PubMed ID: 29045529
[TBL] [Abstract][Full Text] [Related]
4. MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer.
Parikh AR; Lee FC; Yau L; Koh H; Knost J; Mitchell EP; Bosanac I; Choong N; Scappaticci F; Mancao C; Lenz HJ
Clin Cancer Res; 2019 May; 25(10):2988-2995. PubMed ID: 30224341
[TBL] [Abstract][Full Text] [Related]
5. Predictive value of TLR7 polymorphism for cetuximab-based chemotherapy in patients with metastatic colorectal cancer.
Okazaki S; Stintzing S; Sunakawa Y; Cao S; Zhang W; Yang D; Ning Y; Matsusaka S; Berger MD; Miyamoto Y; Suenaga M; Schirripa M; West JD; Gopez R; Akihito T; Ichikawa W; Heinemann V; DePaolo RW; Lenz HJ
Int J Cancer; 2017 Sep; 141(6):1222-1230. PubMed ID: 28569041
[TBL] [Abstract][Full Text] [Related]
6. A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials.
Berger MD; Ning Y; Stintzing S; Heinemann V; Cao S; Zhang W; Yang D; Miyamoto Y; Suenaga M; Schirripa M; Hanna DL; Soni S; Puccini A; Tokunaga R; Naseem M; Battaglin F; Cremolini C; Falcone A; Loupakis F; Lenz HJ
Eur J Cancer; 2020 May; 131():89-97. PubMed ID: 32305727
[TBL] [Abstract][Full Text] [Related]
7. Autophagy-related polymorphisms predict hypertension in patients with metastatic colorectal cancer treated with FOLFIRI and bevacizumab: Results from TRIBE and FIRE-3 trials.
Berger MD; Yamauchi S; Cao S; Hanna DL; Sunakawa Y; Schirripa M; Matsusaka S; Yang D; Groshen S; Zhang W; Ning Y; Okazaki S; Miyamoto Y; Suenaga M; Lonardi S; Cremolini C; Falcone A; Heinemann V; Loupakis F; Stintzing S; Lenz HJ
Eur J Cancer; 2017 May; 77():13-20. PubMed ID: 28347919
[TBL] [Abstract][Full Text] [Related]
8. Relevance of baseline carcinoembryonic antigen for first-line treatment against metastatic colorectal cancer with FOLFIRI plus cetuximab or bevacizumab (FIRE-3 trial).
Holch JW; Ricard I; Stintzing S; Fischer von Weikersthal L; Decker T; Kiani A; Vehling-Kaiser U; Heintges T; Kahl C; Kullmann F; Scheithauer W; Moehler M; Jelas I; Modest DP; Westphalen CB; von Einem JC; Michl M; Heinemann V
Eur J Cancer; 2019 Jan; 106():115-125. PubMed ID: 30496943
[TBL] [Abstract][Full Text] [Related]
9. A Polymorphism within the Vitamin D Transporter Gene Predicts Outcome in Metastatic Colorectal Cancer Patients Treated with FOLFIRI/Bevacizumab or FOLFIRI/Cetuximab.
Berger MD; Stintzing S; Heinemann V; Cao S; Yang D; Sunakawa Y; Matsusaka S; Ning Y; Okazaki S; Miyamoto Y; Suenaga M; Schirripa M; Hanna DL; Soni S; Puccini A; Zhang W; Cremolini C; Falcone A; Loupakis F; Lenz HJ
Clin Cancer Res; 2018 Feb; 24(4):784-793. PubMed ID: 29208668
[No Abstract] [Full Text] [Related]
10. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
11. Validation of miR-31-3p Expression to Predict Cetuximab Efficacy When Used as First-Line Treatment in
Laurent-Puig P; Grisoni ML; Heinemann V; Liebaert F; Neureiter D; Jung A; Montestruc F; Gaston-Mathe Y; Thiébaut R; Stintzing S
Clin Cancer Res; 2019 Jan; 25(1):134-141. PubMed ID: 30108104
[TBL] [Abstract][Full Text] [Related]
12. Prognostic Value of ACVRL1 Expression in Metastatic Colorectal Cancer Patients Receiving First-line Chemotherapy With Bevacizumab: Results From the Triplet Plus Bevacizumab (TRIBE) Study.
Hanna DL; Loupakis F; Yang D; Cremolini C; Schirripa M; Li M; Matsusaka S; Berger MD; Miyamoto Y; Zhang W; Ning Y; Antoniotti C; Salvatore L; Moran M; Zeger G; Astrow SH; Falcone A; Lenz HJ
Clin Colorectal Cancer; 2018 Sep; 17(3):e471-e488. PubMed ID: 29636300
[TBL] [Abstract][Full Text] [Related]
13. Clinical Significance of TLR1 I602S Polymorphism for Patients with Metastatic Colorectal Cancer Treated with FOLFIRI plus Bevacizumab.
Okazaki S; Loupakis F; Stintzing S; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Stremitzer S; Matsusaka S; Berger MD; Parekh A; West JD; Miyamoto Y; Suenaga M; Schirripa M; Cremolini C; Falcone A; Heinemann V; DePaolo RW; Lenz HJ
Mol Cancer Ther; 2016 Jul; 15(7):1740-5. PubMed ID: 27196764
[TBL] [Abstract][Full Text] [Related]
14. Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.
Matsusaka S; Hanna DL; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Okazaki S; Berger MD; Miyamato Y; Parekh A; Stintzing S; Loupakis F; Lenz HJ
Clin Cancer Res; 2016 Jul; 22(13):3218-26. PubMed ID: 26839145
[TBL] [Abstract][Full Text] [Related]
15. Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancer.
Arai H; Millstein J; Loupakis F; Stintzing S; Wang J; Battaglin F; Kawanishi N; Jayachandran P; Soni S; Zhang W; Mumenthaler SM; Cremolini C; Heinemann V; Falcone A; Lenz HJ
Eur J Cancer; 2021 Jun; 150():133-142. PubMed ID: 33901792
[TBL] [Abstract][Full Text] [Related]
16. Single nucleotide polymorphisms in the IGF-IRS pathway are associated with outcome in mCRC patients enrolled in the FIRE-3 trial.
Schirripa M; Zhang W; Heinemann V; Cao S; Okazaki S; Yang D; Loupakis F; Berger MD; Ning Y; Miyamoto Y; Suenaga M; Gopez RF; West JD; Hanna D; Barzi A; Falcone A; Stintzing S; Lenz HJ
Int J Cancer; 2017 Jul; 141(2):383-392. PubMed ID: 28369940
[TBL] [Abstract][Full Text] [Related]
17. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
Cremolini C; Loupakis F; Antoniotti C; Lupi C; Sensi E; Lonardi S; Mezi S; Tomasello G; Ronzoni M; Zaniboni A; Tonini G; Carlomagno C; Allegrini G; Chiara S; D'Amico M; Granetto C; Cazzaniga M; Boni L; Fontanini G; Falcone A
Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
[TBL] [Abstract][Full Text] [Related]
18. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
[TBL] [Abstract][Full Text] [Related]
19. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.
Cremolini C; Loupakis F; Masi G; Lonardi S; Granetto C; Mancini ML; Chiara S; Moretto R; Rossini D; Vitello S; Allegrini G; Tonini G; Bergamo F; Tomasello G; Ronzoni M; Buonadonna A; Bustreo S; Barbara C; Boni L; Falcone A
Ann Oncol; 2016 May; 27(5):843-9. PubMed ID: 26861604
[TBL] [Abstract][Full Text] [Related]
20. The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT].
Clarke SJ; Burge M; Feeney K; Gibbs P; Jones K; Marx G; Molloy MP; Price T; Reece WHH; Segelov E; Tebbutt NC
PLoS One; 2020; 15(3):e0229900. PubMed ID: 32142532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
